CLINICAL_TRIALS
trial_result
· 2021-01-13
Clinical Trial Update: Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells [Phase 2]
Summary
Phase 2 trial evaluating nilotinib 300 mg twice daily in newly diagnosed chronic-phase CML to verify disappearance of CD34+/Lin-Ph+ cells.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Niguarda Hospital | Conditions: Leukemia, Myeloid, Chronic-Phase | Phase 2 | Status: COMPLETED